CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 23(Granted Patents)

Company Filing History:

Years Active: 2013-2022

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11466089 - Chemokine receptor binding polypeptides (2022-10-11),

2. 10174118 - Nucleic acids encoding chemokine receptor binding polypeptides (2019-01-08),

3. 9688763 - Chemokine receptor binding polypeptides (2017-06-27),

4. 9604981 - IP receptor agonist heterocyclic compounds (2017-03-28),

5. 9328174 - Chemokine receptor binding polypeptides (2016-05-03),

6. 9132127 - Substituted pyrido[2,3-B]pyrazines as IP receptor agonists (2015-09-15),

7. 9127067 - Methods of treatment using chemokine receptor binding polypeptides (2015-09-08),

8. 9115129 - Substituted pyrido[2,3-B]pyrazines as IP receptor agonists (2015-08-25),

9. 8754085 - Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist (2014-06-17),

10. 8591896 - Chemokine receptor binding polypeptides (2013-11-26),

Title: Steven John Charlton: Pioneering Innovator in Polypeptides

Introduction:

Steven John Charlton, hailing from Horsham, GB, stands as a remarkable inventor with a notable contribution in the field of polypeptides. With an impressive portfolio of 10 patents to his name, Charlton has significantly advanced the landscape of science and medicine.

Latest Patents:

Charlton's recent patents revolve around the development of polypeptides targeting the C-X-C Motif chemokine receptor 2 (CXCR2). These polypeptides possess the capability to modulate signal transduction from CXCR2, offering potential treatments for diseases associated with CXCR2 malfunction. His innovative work also extends to nucleic acids, vectors, and host cells for expressing these polypeptides, paving the way for novel pharmaceutical compositions.

Career Highlights:

Having collaborated with renowned companies such as Novartis AG and Ablynx N.V., Charlton has left a lasting impact in the pharmaceutical industry. His expertise in polypeptide research has been instrumental in shaping the development of therapeutic interventions for CXCR2-related conditions.

Collaborations:

Throughout his esteemed career, Charlton has had the privilege of working alongside accomplished professionals like Zarin Brown and Michelle Bradley. Together, they have synergized their talents to drive forward innovation and scientific progress in the realm of polypeptide therapeutics.

Conclusion:

In conclusion, Steven John Charlton emerges as a pioneering force in the realm of polypeptides, leveraging his inventive prowess to address critical medical needs. His dedication to advancing scientific knowledge and his impactful collaborations underscore Charlton's contributions to the field, leaving a lasting legacy in the world of pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.